Dose-escalated stereotactic body radiotherapy re-irradiation in patients with recurrent head and neck cancer: a prospective phase 2 study using automated non-coplanar volumetric modulated arc therapy

By afschroeder • November 17, 2025

Nikitas J, Ma TM, Cook K, Woods K, Kishan AU, Reddy VK, Hegde JV, John MS, Chai-Ho W, Wong D, Chu FI, Felix C, Tenn S, Sheng K, Steinberg ML, Kadowaki JY, Pham J, O'Connell DP, Cao M, Chin RK. Dose-escalated stereotactic body radiotherapy re-irradiation in patients with recurrent head and neck cancer: a prospective phase 2 study using automated non-coplanar volumetric modulated arc therapy. Radiother Oncol. 2025 Nov 14:111283. doi: 10.1016/j.radonc.2025.111283. Epub ahead of print. PMID: 41242408.

Tags: Hematology/Oncology, Publications

Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study

Timmerman J, Lavie D, Johnson NA, Avigdor A, Borchmann P, Andreadis C, Bazargan A, Gregory GP, Keane C, Tzoran I, Vucinic V, Zinzani PL, West[...]

A Phase 1 Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients With Advanced Gastrointestinal Cancers

Fakih M, Doi T, Tolcher A, Hong D, Tie J, Messersmith W, Koyama T, Rosen L, Borlido J, Damore MA, Delioukina M, Cheronis I, Clark[...]

Demystifying financial toxicity measures: semi-structured interviews comparing COST-FACIT and ENRICh among cancer survivors on targeted oral anticancer medications (TOAMs)

Lowenstein LM, Bernal MP, Bergren EP, Busaidy TK, Brauer ER, Ganz PA, Smith GL, Shih YT. Demystifying financial toxicity measures: semi-structured interviews comparing COST-FACIT and[...]